Evidence map›Paper›PMID 35066769›Full record

ArticleMolecular biology reports2022

The role of FOXC1/FOXCUT/DANCR axis in triple negative breast cancer: a bioinformatics and experimental approach.

Zeeba Kamaliyan, Reza Mirfakhraie, Ghasem Azizi-Tabesh, Farzaneh Darbeheshti, Ramesh Omranipour, Nasrin Ahmadinejad, Elham Zokaei, Vahid-Reza Yassaee

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. The Role of the Fox Gene in Breast Cancer Progression.International journal of molecular sciences · 2025
    Review
  2. Recent advances and updated highlights in breast cancer pathologic diagnosis: a narrative review.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025
    Review
  3. Article
  4. Unlocking epigenetics for precision treatment of Ewing's sarcoma.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2024
    Article
  5. Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Zeeba KamaliyanDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar St, Velenjak Ave, Chamran Highway, 19395-4719, Tehran, Iran.
Reza MirfakhraieDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar St, Velenjak Ave, Chamran Highway, 19395-4719, Tehran, Iran. reza_mirfakhraie@yahoo.com.ORCID http://orcid.org/0000-0003-1709-8975
Ghasem Azizi-TabeshDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar St, Velenjak Ave, Chamran Highway, 19395-4719, Tehran, Iran.
Farzaneh DarbeheshtiDepartment of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Ramesh OmranipourBreast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran.
Nasrin AhmadinejadMedical Imaging Center, Cancer Research Institute, Imam Khomeini Hospital Advanced Diagnostic and Interventional Radiology Research Center (ADIR), Tehran University of Medical Sciences (TUMS), Tehran, Iran.
Elham ZokaeiDepartment of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.
Vahid-Reza YassaeeDepartment of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Koodakyar St, Velenjak Ave, Chamran Highway, 19395-4719, Tehran, Iran. v.yassaee-grc@sbmu.ac.ir.ORCID http://orcid.org/0000-0002-1879-3905
Shahid Beheshti University of Medical Sciences · IRTehran University of Medical Sciences · IRImam Khomeini Hospital · IRShahid Bahonar University of Kerman · IR

Funding

research department of the school of medicine, shahid beheshti university of medical sciences 25169
6 · The paper itself

Abstract

backgroundTriple-negative breast cancer (TNBC) is the most challenging subtype of breast cancer and does not benefit from the existing targeted therapies. In the present study, we used bioinformatics and experimental approaches to assess the genes that are somehow involved in the epithelial-mesenchymal transition (EMT) pathway which may explain the invasive features of TNBC. METHOD AND

resultsWe analyzed five GEO datasets consisting of 657 breast tumors by GEO2R online software to achieve common differentially expressed genes (DEGs) between TNBC and non-TNBC tumors. The expression of the selected coding and non-coding genes was validated in 100 breast tumors, including fifty TNBC and fifty non-TNBC samples, using quantitative Real-Time PCR (qRT-PCR). The bioinformatics approach resulted in a final DEG list consisting of ten upregulated and seventeen downregulated genes (logFC ≥|1| and P < 0.05). Co-expression network construction indicated the FOXC1 transcription factor as a central hub node. Considering the notable role of FOXC1 in EMT, the expression levels of FOXC1-related lncRNAs, lnc-FOXCUT and lnc-DANCR, were also evaluated in the studied tumors. The results of qRT-PCR confirmed notable upregulation of FOXC1, lnc-FOXCUT, and lnc-DANCR in TNBC tissues compared to non-TNBC samples (P < 0.0001, P = 0.0005, and P = 0.0008, respectively). Moreover, ROC curve analysis revealed the potential biomarker role of FOXC1 in TNBC samples.

conclusionPresent study suggested that the deregulation of FOXC1/lnc-FOXCUT/lnc-DANCR axis may contribute to the aggressive features of triple-negative breast tumors. Therefore, this axis may be considered as a new probable therapeutic target in the treatment of TNBC.

Indexed as

RNA, Long NoncodingTriple Negative Breast NeoplasmsCell Line, TumorComputational BiologyForkhead Transcription FactorsGene Expression Regulation, NeoplasticHumansDANCR long noncoding RNA, humanForkhead Transcription FactorsFOXC1 protein, humanlong non-coding RNA FOXCUT, humanRNA, Long NoncodingBioinformaticsFOXC1Lnc-DANCRLnc-FOXCUTTriple-negative breast cancer

Identifiers

PMID35066769
OpenAlexW4206995082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.